Abstract
Objective
To determine diagnostic accuracy and evaluate the predictive value of autoantibody profiles in patients with systemic sclerosis (SSc).
Methods
A total of 140 patients with SSc (125 female, mean age 54.2 ± 14.2 years) were analyzed by a multiplex line immunoassay (Euroimmun) for autoantibodies against 12 SSc-related antigens. Associations between the presence of the autoantibodies and demographic clinical manifestations of patients with SSc were investigated.
Results
The sensitivity and specificity of this assay were as follows: 32.9% and 99.4% for anti-Scl-70, 29.3% and 88.9% for anti-CENP A, 28.6% and 87.8% for anti-CENP B, 7.1% and 97.8% for anti-RP11, 5.7% and 100% for anti-RP155, 2.9% and 99.4% for anti-NOR 90, 2.9% and 98.9% for anti-Th/To, 1.4% and 96.7% for anti-PM-Scl-100, 5.0% and 98.3% for anti-PM-Scl-75, and 2.9% and 97.2% for anti-Ku, respectively. Anti-Scl-70 was significantly associated with sine scleroderma (P = 0.003), digital ulcers (P = 0.047), and Raynaud’s phenomenon as the first clinical manifestation of onset (P = 0.017). SSc-ILD was more common in patients with anti-Scl-70 (P = 0.029) and less frequent in patients with anti-CENP A (P < 0.001) and anti-CENP B (P < 0.001). There was a significant association between PAH with anti-CENP A (P = 0.008) and anti-CENP B (P = 0.025). Renal involvement was significantly related to anti-NOR90 (P = 0.026) and anti-Th/To (P = 0.026).
Conclusions
This study confirmed the important role of autoantibodies in accurately diagnosing SSc. The autoimmune profile of patients with SSc was related to specific disease manifestations.
Key Points • Autoantibody profiles were useful for diagnosing SSc and predicting clinical features of patients. |
Similar content being viewed by others
Data availability
The data supporting the findings in this study will be available from the corresponding author on request.
References
Denton CP, Khanna D (2017) Systemic sclerosis. Lancet 390(10103):1685–1699
Poudel DR, Derk CT (2018) Mortality and survival in systemic sclerosis: a review of recent literature. Curr Opin Rheumatol 30(6):588–593
Pauling JD, McGrogan A, Snowball J, McHugh NJ (2021) Epidemiology of systemic sclerosis in the UK: an analysis of the Clinical Practice Research Datalink. Rheumatology (Oxford) 60(6):2688–2696
Mehra S, Walker J, Patterson K, Fritzler MJ (2013) Autoantibodies in systemic sclerosis. Autoimmun Rev 12(3):340–354
Chang WS, Schollum J, White DH, Solanki KK (2015) A cross-sectional study of autoantibody profiles in the Waikato systemic sclerosis cohort New Zealand. Clin Rheumatol 34(11):1921–1927
Czompoly T, Simon D, Czirjak L, Nemeth P (2009) Anti-topoisomerase I autoantibodies in systemic sclerosis. Autoimmun Rev 8(8):692–696
van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, Matucci-Cerinic M, Naden RP, Medsger TA Jr, Carreira PE et al (2013) 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis 72(11):1747–1755
Jantarat A, Muangchan C (2022) Epidemiology and clinical characteristics of systemic sclerosis overlap syndrome (SSc-OS), and the factors significantly associated with SSc-OS in Thai patients with systemic sclerosis. Mod Rheumatol 32(5):899–907
Bussone G, Mouthon L (2011) Interstitial lung disease in systemic sclerosis. Autoimmun Rev 10(5):248–255
Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, Elliott CG, Gaine SP, Gladwin MT, Jing ZC et al (2009) Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 54(1 Suppl):S43–S54
Bruni C, De Luca G, Lazzaroni MG, Zanatta E, Lepri G, Airo P, Dagna L, Doria A, Matucci-Cerinic M (2020) Screening for pulmonary arterial hypertension in systemic sclerosis: a systematic literature review. Eur J Intern Med 78:17–25
Campo A, Mathai SC, Le Pavec J, Zaiman AL, Hummers LK, Boyce D, Housten T, Champion HC, Lechtzin N, Wigley FM et al (2010) Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension. Am J Respir Crit Care Med 182(2):252–260
Hashimoto A, Endo H, Kondo H, Hirohata S (2012) Clinical features of 405 Japanese patients with systemic sclerosis. Mod Rheumatol 22(2):272–279
Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T et al (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150(9):604–612
Woodworth TG, Suliman YA, Furst DE, Clements P (2016) Scleroderma renal crisis and renal involvement in systemic sclerosis. Nat Rev Nephrol 12(11):678–691
Kowalska-Kepczynska A (2022) Systemic scleroderma-definition, clinical picture and laboratory diagnostics. J Clin Med 11(9):2299–2320
Shreiner AB, Murray C, Denton C, Khanna D (2016) Gastrointestinal manifestations of systemic sclerosis. J Scleroderma Relat Disord 1(3):247–256
Bardou P, Mariette J, Escudie F, Djemiel C, Klopp C (2014) jvenn: an interactive Venn diagram viewer. BMC Bioinformatics 15:293
Douvas AS, Achten M, Tan EM (1979) Identification of a nuclear protein (Scl-70) as a unique target of human antinuclear antibodies in scleroderma. J Biol Chem 254(20):10514–10522
Liu C, Hou Y, Yang Y, Xu D, Li L, Li J, Wen X, Zeng X, Zhang F, Li Y (2019) Evaluation of a commercial immunoassay for autoantibodies in Chinese Han systemic sclerosis population. Clin Chim Acta 491:121–125
Moon KW, Lee SS, Lee YJ, Jun JB, Yoo SJ, Ju JH, Chang SH, Choi IA, Kang TY, Lee EB et al (2018) Clinical and Laboratory characteristics and mortality in Korean patients with systemic sclerosis: a nationwide multicenter retrospective cohort study. J Rheumatol 45(9):1281–1288
Nandiwada SL, Peterson LK, Mayes MD, Jaskowski TD, Malmberg E, Assassi S, Satoh M, Tebo AE (2016) Ethnic differences in autoantibody diversity and hierarchy: more clues from a US cohort of patients with systemic sclerosis. J Rheumatol 43(10):1816–1824
Reveille JD, Solomon DH (2003) American College of Rheumatology Ad Hoc Committee of Immunologic Testing G: Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70, and nucleolar antibodies. Arthritis Rheum 49(3):399–412
Low AH, Wong S, Thumboo J, Ng SC, Lim JY, Ng X, Earnest A, Fong KY (2012) Evaluation of a new multi-parallel line immunoassay for systemic sclerosis-associated antibodies in an Asian population. Rheumatology (Oxford) 51(8):1465–1470
Cappelli S, Bellando Randone S, Camiciottoli G, De Paulis A, Guiducci S, Matucci-Cerinic M (2015) Interstitial lung disease in systemic sclerosis: where do we stand? Eur Respir Rev 24(137):411–419
Bohelay G, Blaise S, Levy P, Claeys A, Baudot N, Cuny JF, Maillard H, Granel-Brocard F, Boye T, Lok C et al (2018) Lower-limb ulcers in systemic sclerosis: a multicentre retrospective case-control study. Acta Derm Venereol 98(7):677–682
Wirz EG, Jaeger VK, Allanore Y, Riemekasten G, Hachulla E, Distler O, Airo P, Carreira PE, Tikly M, Vettori S et al (2016) Incidence and predictors of cutaneous manifestations during the early course of systemic sclerosis: a 10-year longitudinal study from the EUSTAR database. Ann Rheum Dis 75(7):1285–1292
Radic M, Martinovic Kaliterna D, Ljutic D (2006) The level of anti-topoisomerase I antibodies highly correlates with metacarpophalangeal and proximal interphalangeal joints flexion contractures in patients with systemic sclerosis. Clin Exp Rheumatol 24(4):407–412
Liaskos C, Marou E, Simopoulou T, Barmakoudi M, Efthymiou G, Scheper T, Meyer W, Bogdanos DP, Sakkas LI (2017) Disease-related autoantibody profile in patients with systemic sclerosis. Autoimmunity 50(7):414–421
Hudson M, Mahler M, Pope J, You D, Tatibouet S, Steele R, Baron M (2012) Investigators of the Canadian Scleroderma Research G, Fritzler M: Clinical correlates of CENP-A and CENP-B antibodies in a large cohort of patients with systemic sclerosis. J Rheumatol 39(4):787–794
Hanke K, Becker MO, Brueckner CS, Meyer W, Janssen A, Schlumberger W, Hiepe F, Burmester GR, Riemekasten G (2010) Anticentromere-A and anticentromere-B antibodies show high concordance and similar clinical associations in patients with systemic sclerosis. J Rheumatol 37(12):2548–2552
Hamaguchi Y, Kodera M, Matsushita T, Hasegawa M, Inaba Y, Usuda T, Kuwana M, Takehara K, Fujimoto M (2015) Clinical and immunologic predictors of scleroderma renal crisis in Japanese systemic sclerosis patients with anti-RNA polymerase III autoantibodies. Arthritis Rheumatol 67(4):1045–1052
Liu C, Hou Y, Xu D, Li L, Zhang Y, Cheng L, Yan S, Zhang F, Li Y (2020) Analysis of anti-RNA polymerase III antibodies in Chinese Han systemic sclerosis patients. Clin Rheumatol 39(4):1191–1197
Okano Y, Steen VD, Medsger TA Jr (1993) Autoantibody reactive with RNA polymerase III in systemic sclerosis. Ann Intern Med 119(10):1005–1013
Meyer O, De Chaisemartin L, Nicaise-Roland P, Cabane J, Tubach F, Dieude P, Hayem G, Palazzo E, Chollet-Martin S, Kahan A et al (2010) Anti-RNA polymerase III antibody prevalence and associated clinical manifestations in a large series of French patients with systemic sclerosis: a cross-sectional study. J Rheumatol 37(1):125–130
Bardoni A, Rossi P, Salvini R, Bobbio-Pallavicini F, Caporali R, Montecucco C (2003) Autoantibodies to RNA-polymerases in Italian patients with systemic sclerosis. Clin Exp Rheumatol 21(3):301–306
Iniesta Arandia N, Espinosa G, Guillen Del Castillo A, Tolosa-Vilella C, Colunga-Arguelles D, de Echavarri Gonzalez, Perez de Heredia C, Lledo GM, Comet LS, Ortego-Centeno N, Vargas Hito JA et al (2022) Anti-polymyositis/scl antibodies in systemic sclerosis: clinical associations in a multicentric spanish cohort and review of the literature. J Clin Rheumatol 28(1):e180–e188
Lazzaroni MG, Marasco E, Campochiaro C, DeVries-Bouwstra J, Gonzalez-Perez MI, Rojas-Serrano J, Hachulla E, Zanatta E, Barsotti S, Furini F et al (2021) The clinical phenotype of systemic sclerosis patients with anti-PM/Scl antibodies: results from the EUSTAR cohort. Rheumatology 60(11):5028–5041
Muro Y, Hosono Y, Sugiura K, Ogawa Y, Mimori T, Akiyama M (2015) Anti-PM/Scl antibodies are found in Japanese patients with various systemic autoimmune conditions besides myositis and scleroderma. Arthritis Res Ther 17:57
Vandergheynst F, Ocmant A, Sordet C, Humbel RL, Goetz J, Roufosse F, Cogan E, Sibilia J (2006) Anti-pm/scl antibodies in connective tissue disease: clinical and biological assessment of 14 patients. Clin Exp Rheumatol 24(2):129–133
D’Aoust J, Hudson M, Tatibouet S, Wick J (2014) Canadian Scleroderma Research G, Mahler M, Baron M, Fritzler MJ: Clinical and serologic correlates of anti-PM/Scl antibodies in systemic sclerosis: a multicenter study of 763 patients. Arthritis Rheumatol 66(6):1608–1615
Koschik RW 2nd, Fertig N, Lucas MR, Domsic RT, Medsger TA Jr (2012) Anti-PM-Scl antibody in patients with systemic sclerosis. Clin Exp Rheumatol 30(2 Suppl 71):S12-16
Kuwana M, Kimura K, Hirakata M, Kawakami Y, Ikeda Y (2002) Differences in autoantibody response to Th/To between systemic sclerosis and other autoimmune diseases. Ann Rheum Dis 61(9):842–846
Suresh S, Charlton D, Snell EK, Laffoon M, Medsger TA, Jr., Zhu L, Domsic RT (2022) Development of pulmonary hypertension in over one-third of patients with Th/To antibody-positive scleroderma in long-term follow-up. Arthritis Rheumatol 74(9):1580–1587
Mitri GM, Lucas M, Fertig N, Steen VD, Medsger TA Jr (2003) A comparison between anti-Th/To- and anticentromere antibody-positive systemic sclerosis patients with limited cutaneous involvement. Arthritis Rheum 48(1):203–209
Yamashita Y, Yamano Y, Muro Y, Ogawa-Momohara M, Takeichi T, Kondoh Y, Akiyama M (2022) Clinical significance of anti-NOR90 antibodies in systemic sclerosis and idiopathic interstitial pneumonia. Rheumatology 61(4):1709–1716
Belizna C, Henrion D, Beucher A, Lavigne C, Ghaali A, Levesque H (2010) Anti-Ku antibodies: clinical, genetic and diagnostic insights. Autoimmun Rev 9(10):691–694
Franceschini F, Cavazzana I, Generali D, Quinzanini M, Viardi L, Ghirardello A, Doria A, Cattaneo R (2002) Anti-Ku antibodies in connective tissue diseases: clinical and serological evaluation of 14 patients. J Rheumatol 29(7):1393–1397
Ho KT, Reveille JD (2003) The clinical relevance of autoantibodies in scleroderma. Arthritis Res Ther 5(2):80–93
Reveille JD (2003) Ethnicity and race and systemic sclerosis: how it affects susceptibility, severity, antibody genetics, and clinical manifestations. Curr Rheumatol Rep 5(2):160–167
Mahler M, Kim G, Roup F, Bentow C, Fabien N, Goncalves D, Palterer B, Fritzler MJ, Villalta D (2021) Evaluation of a novel particle-based multi-analyte technology for the detection of anti-fibrillarin antibodies. Immunol Res 69(3):239–248
Classen JF, Henrohn D, Rorsman F, Lennartsson J, Lauwerys BR, Wikstrom G, Rorsman C, Lenglez S, Franck-Larsson K, Tomasi JP et al (2009) Lack of evidence of stimulatory autoantibodies to platelet-derived growth factor receptor in patients with systemic sclerosis. Arthritis Rheum 60(4):1137–1144
Paolini C, Agarbati S, Benfaremo D, Mozzicafreddo M, Svegliati S, Moroncini G (2022) PDGF/PDGFR: a possible molecular target in scleroderma fibrosis. Int J Mol Sci 23(7):3904–3916
Bruni C, Cuomo G, Rossi FW, Praino E, Bellando-Randone S (2018) Kidney involvement in systemic sclerosis: from pathogenesis to treatment. J Scleroderma Relat Disord 3(1):43–52
Hesselstrand R, Scheja A, Wuttge DM (2012) Scleroderma renal crisis in a Swedish systemic sclerosis cohort: survival, renal outcome, and RNA polymerase III antibodies as a risk factor. Scand J Rheumatol 41(1):39–43
Hruskova Z, Pippias M, Stel VS, Abad-Díez JM, Benítez Sánchez M, Caskey FJ, Collart F, De Meester J, Finne P, Heaf JG et al (2019) Characteristics and outcomes of patients with systemic sclerosis (scleroderma) requiring renal replacement therapy in Europe: results from the ERA-EDTA registry. Am J Kidney Dis 73(2):184–193
Funding
This work was supported by the China International Medical Foundation (No. Z-2018–40-2101), the National Natural Science Foundation of China (No.81871281), and the Beijing Natural Science Foundation (7192211).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosures
None.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Zhang, X., Zhang, H., Zhao, J. et al. Diagnostic accuracy and predictive value of autoantibody profiles in patients with systemic sclerosis: a single-center study. Clin Rheumatol 42, 1297–1306 (2023). https://doi.org/10.1007/s10067-022-06487-3
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-022-06487-3